Navigation Links
VistaGen, WARF sign license agreement for human embryonic stem cell technology
Date:12/18/2008

MADISON, VistaGen Therapeutics and the Wisconsin Alumni Research Foundation (WARF) have signed a license for human embryonic stem cell patents for the development and commercialization of stem cell-based research tools.

VistaGen, a biotechnology company based in South San Francisco, is one of the world's leading companies focused on using the power of stem cell technology to transform the ways drugs are discovered and tested. WARF is the private, non-profit patenting and licensing organization for the University of Wisconsin-Madison, one of the top-ranked public research universities in the U.S.

The licensed patents result from the research of stem cell pioneer James Thompson of the University of Wisconsin Stem Cell and Regenerative Medicine Center and director of regenerative biology at the new Morgridge Institute for Research. The license will accelerate VistaGen's commercial programs focused on providing customized, next-generation, stem cell-based predictive toxicology and drug discovery screening assays to increase preclinical research and development (R&D) productivity for the pharmaceutical industry.

"This agreement with WARF is another critical step in our strategy to become a 'one-stop-shop' for the world's premier stem cell differentiation systems," says Ralph Snodgrass, VistaGen's CEO. "It enhances our fundamental expertise for capturing the value of human embryonic stem cell biology for predictive toxicology, drug discovery screening and drug development. When combined with our strong stem cell-based intellectual property estate, the key terms of the new license provide a strong foundation to support our commercial programs focused on high-end R&D services, strategic discovery collaborations and enabling licenses."

"We are very pleased to have signed a licensing agreement with VistaGen," says Andy DeTienne, WARF's licensing manager for stem cell technologies. "VistaGen's approach to the commercialization of human embryonic stem cell technologies as next-generation tools for drug discovery and development in the pharmaceutical industry strongly complements our ongoing efforts to support growth of the human ES cell industry." He notes this licensing agreement with VistaGen demonstrates that commercial interest in human embryonic stem cells remains strong.

In 2009, VistaGen expects to launch a new era of R&D productivity in the pharmaceutical industry, an era driven by clinically relevant, commercially scalable, human biology-based screening systems capable of predicting the safety and efficacy of new drugs in ways never before possible. The company plans to use predictive information from its stem cell-based "Clinical Trials in a Test Tube" to increase the efficiency of identifying effective drug candidates and reduce clinical trial failures, especially failures due to heart or liver toxicity. VistaGen expects its next-generation stem cell-based human systems biology platform to dramatically enhance the pharmaceutical industry's ability to deliver innovative drugs for some of the world's most challenging diseases and conditions.


'/>"/>

Contact: Janet L. Kelly
jkelly@warf.org
608-890-1491
University of Wisconsin-Madison
Source:Eurekalert

Related biology news :

1. L-1 Identity Solutions Awarded New Massachusetts RMV Drivers License Contract Valued at an Estimated $32 Million
2. L-1 Identity Solutions Receives $5.9 Million Drivers License Contract Expansion from the State of Mississippi
3. Syntermed licenses Emory ERTb software for enhanced cardiac imaging
4. Iowa Corn Promotion Board, NJIT to license breakthrough, safe bio-plastic alternative
5. FSU, Magnet Lab researchers license critical petroleum data
6. Pfizer inks global license to Genomatix Software and databases
7. Integrated Fuel Technologies gets worldwide license for Argonne-developed Diesel DeNOx Catalyst
8. New high fiber barley licensed to grow
9. Springer and the Physiological Society of Japan sign publishing agreement
10. Saving Sumatra: Indonesia reaches historic agreement
11. Zebra Technologies Enters Into Revolving Credit Agreement to Support Company Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 The ... apparently one of the most popular hubs of ... MetaHIT and other huge studies of human microbiota, ... past few years, the microbiome space has literally ... biomedical research. This report focuses on biomedical ...
(Date:2/3/2016)... Feb. 3, 2016 ... of the "Emotion Detection and Recognition ... and Others), Software Tools (Facial Expression, Voice ... Users,and Regions - Global forecast to 2020" ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the ...
(Date:2/2/2016)... , Feb. 2, 2016 Technology Enhancements Accelerate ... an analysis of the digital and computed radiography markets ... , and Indonesia (TIM). ... and market size, as well as regional market drivers ... and discusses market penetration and market attractiveness, both for ...
Breaking Biology News(10 mins):
(Date:2/9/2016)... ... ... The American Academy of Thermology (AAT) has announced that for ... Certification Qualification Course for Technicians via a two part webinar on July 30 and ... review of hardware, software, and camera setup/operations, aligns with the in-person member qualification course ...
(Date:2/9/2016)... , Feb. 9, 2016 This market ... the current and future prospects of the market in ... report include companies engaged in the manufacture of microbiology ... executive summary with a market snapshot providing the overall ... of this report. This section also provides the overall ...
(Date:2/9/2016)... LONDON , Feb. 9, 2016 /PRNewswire/ ... (PTP1B) Inhibitors-Pipeline Insights, 2016", report provides in ... their development activities around the Protein-Tyrosine Phosphatase ... the product profiles in various stages of ... Phase II, Phase III and Preregistration. Report ...
(Date:2/8/2016)... February 8, 2016 ... Limited, an innovation-driven oncology company developing next generation ... toxic, today announced that chairman emeritus of Tata ... in the company as part of the first ... existing investors Navam Capital and Aarin Capital. ...
Breaking Biology Technology: